ADB-FUBHQUCA.

ADB-FUBHQUCA takes up the classic architecture of synthetic cannabinoids, a 4-fluorobenzyl chain, a carboxamide bridge and a tert-leucinamide group, but replaces the usual indole or indazole ring with a non-aromatic 1,4-dihydroquinoline. This modification of the core of the molecule has the effect of placing the substance outside the scope of French generic definitions drafted around indole and indazole. Pharmacologically, the file is empty. The British ACMD committee, which recorded it in 2023, states that no information is available, and a literature search finds no study having measured its activity: no affinity or efficacy at CB1 and CB2, no pharmacokinetics, no metabolism, no toxicology specific to this molecule. Human data are entirely lacking, and its classification among cannabinoid receptor agonists remains a structural inference. This void is in itself a major limitation: for the class of synthetic agonists, the ACMD describes confusion, agitation, psychosis, seizures, cardiac rhythm disturbances and liver or kidney failure, sometimes fatal, and nothing makes it possible to place ADB-FUBHQUCA on that scale.

Source

No natural origin. It is not a constituent of hemp and the molecule exists in no plant: it comes entirely from chemical synthesis. The only documented report is a seizure of powder.

No biosynthetic pathway. The molecule has no plant precursor and does not derive from the cannabigerol pathway that produces the cannabinoids of hemp. It belongs to synthetic chemistry alone.

European Union

No control measure at European Union level covers ADB-FUBHQUCA: the molecule has been the subject of no risk assessment report by the EUDA, formerly EMCDDA, and is not listed in the annex of Framework Decision 2004/757/JHA. Nor does it appear in the schedules of the 1971 United Nations Convention, hence no international control. In the United Kingdom, the ACMD committee recorded it in 2023 among the cannabinoid receptor agonists falling outside the scope of the generic definition of the Misuse of Drugs Act, noting the absence of British detections and the uncommon nature of compounds with a hydroquinoline ring. Its status therefore falls to national law.

France

Not scheduled by name in France. The consolidated list of substances classified as narcotics published by ANSM, updated on 16 February 2026, does not mention ADB-FUBHQUCA, whereas it names its analogues ADB-FUBINACA, ADB-PINACA, ADB-CHMINACA and ADB-BUTINACA. The generic clause covering tetrahydrocannabinols, their esters, ethers, salts as well as the salts of the aforementioned derivatives (in annex III of the consolidated list since the decision of 6 February 2026) does not apply here: this molecule is not a tetrahydrocannabinol. The definitions by family of synthetic cannabinoids set out in annex IV are built around exhaustively enumerated rings (indole, indazole, pyrrole, indene, pyrrolo[3,2-c]pyridine, thiazolyl-indole, cyclohexylphenol, benzo[c]chromene), and the 1,4-dihydroquinoline ring of ADB-FUBHQUCA does not appear among them. As the text stands, the substance therefore escapes classification as a narcotic. That does not make it lawful to sell: no food, cosmetic or medicinal authorisation covers it, and scheduling may occur at any moment by ANSM decision.

Sources: EUR-Lex, UNODC, CND, ANSM, IUPHAR/BPS, ChEBI, EUDA. Our method.

Family

Synthetic CB receptor agonist › New psychoactive substance

Class

1,4-dihydroquinoline-3-carboxamide (tert-leucinamide head, 4-fluorobenzyl tail)

Verification

Classification, sources and binding values checked on 20 October 2026; text read against its sources and Wikipedia.

Wikipedia (English)

ADB-FUBHQUCA (new tab)

Article paired by the molecule's structure (InChIKey), revision read on 19 October 2026. Read as a second opinion, never cited as a source.

1. 1ACMD, Cumyl-PeGaClone and other recently encountered synthetic cannabinoid receptor agonists, Home Office, 2023, annex A, entry ADB-FUBHQUCA (hydroquinoline core; no pharmacological information; powder seized by Turkish customs in September 2021; no detection in the United Kingdom) (new tab)
2. 2AIPSIN, New Substance Report 118: ADB-FUBHQUCA, 18 February 2022 (Turkish notification to the European early warning system of 17 February 2022; 2,066 g of yellow powder seized at Istanbul airport; structure confirmed by GC-MS, LC-MS, FTIR and NMR at the University of Ankara; no pharmacological information) (new tab)
3. 3ANSM, consolidated list of substances classified as narcotics, updated 16 February 2026 (new tab)
4. 4PubChem, CID 165361603, N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1,4-dihydroquinoline-3-carboxamide (identifiers and structure) (new tab)

SMILES

CC(C)(C)C(NC(=O)C1=CN(Cc2ccc(F)cc2)c2ccccc2C1)C(N)=O

Machine-readable entry (JSON)

LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.